Impact of rotavirus vaccination on diarrheal disease burden of children in South America.

RotaTeq Rotarix acute gastroenteritis hospitalization intussusception mortality rotavirus

Journal

Expert review of vaccines
ISSN: 1744-8395
Titre abrégé: Expert Rev Vaccines
Pays: England
ID NLM: 101155475

Informations de publication

Date de publication:
30 May 2024
Historique:
medline: 30 5 2024
pubmed: 30 5 2024
entrez: 30 5 2024
Statut: aheadofprint

Résumé

Rotavirus is a leading cause of severe diarrheal disease and death in children under five years of age worldwide. Vaccination is one of the most important public health interventions to reduce this significant burden. This literature review examined vaccination coverage, hospitalization rate, mortality, genotypic distribution, immunogenicity, cost-effectiveness, and risk versus benefit of rotavirus vaccination in children in South America. Nine out of twelve countries in South America currently include a rotavirus vaccine in their national immunization program with coverage rates in 2022 above 90%. Introduction of the rotavirus vaccination has led to a marked reduction in hospitalizations and deaths from diarrheal diseases in children under 5 years, particularly infants under 1 year, in several South American countries. In Brazil, hospitalizations decreased by 59% and deaths by 21% (30-38% in infants). In Peru, hospitalizations in infants fell by 46% and deaths by 37% (56% in infants). Overall, data suggest that rotavirus vaccination has reduced rotavirus deaths by 15-50% in various South American countries. There is some evidence that immunity wanes after the age of 1 year old. Ongoing surveillance of vaccine coverage and changes in morbidity and mortality is important to maximize protection against this disease.

Identifiants

pubmed: 38813689
doi: 10.1080/14760584.2024.2360212
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Tanmoy Bose (T)

Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.

Ray Borrow (R)

Vaccine Evaluation Unit, UK Health Security Agency, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK.

Peter D Arkwright (PD)

Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.

Classifications MeSH